Emergent BioSolutions cuts full-year 2026 revenue and EBITDA guidanceSep 14PeopleEmergent BioSolutions
Scienture launches REZENOPY, cites patent wins and payer gains in Q2 2026 updateAug 20Quarterly updatenaloxoneScienture Holdings, Inc.
Amneal clears five FDA supplements: REMS update on buprenorphine/naloxone leads weekAug 14Weekly roundup, 5 itemsAmneal Pharmaceuticals, LLCbuprenorphine
FDA clears five ANDA supplements for Teva and Actavis Labs generics, mostly labeling updatesAug 14Weekly roundup, 5 itemsTeva Pharmaceutical Industries Ltd
Sun Pharma logs eleven FDA labeling supplements and two REMS updates in one weekAug 14Weekly roundup, 11 itemsisotretinoinSun Pharmaceutical Industries
Emergent BioSolutions posts Q2 revenue surge but takes $191 million impairment, cuts 2026 outlookAug 5RestructuringEmergent BioSolutions
Sign inSign in